Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs TRXE 002 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Kazia Therapeutics
- 28 Mar 2018 According to a Kazia Therapeutics media release, initial data anticipated in 2Q 2018.
- 11 Dec 2017 Novogen company name has changed to Kazia Therapeutics Limited.
- 07 Aug 2017 According to a Novogen media release, the company anticipates MTD results in the first quarter of 2018 and the exploratory efficacy data from the additional patients will be available later in 2018.